Bavarian Nordic Awarded Another Contract to Supply Smallpox Vaccines for EU Strategic Reserve
2023年9月13日 - 6:32PM
Bavarian Nordic Awarded Another Contract to Supply Smallpox
Vaccines for EU Strategic Reserve
COPENHAGEN, Denmark, September 13, 2023 –
Bavarian Nordic A/S (OMX: BAVA) announced today, that it has been
awarded another contract valued at more than EUR 11 million to
supply its MVA-BN® smallpox vaccine to rescEU, a strategic reserve
within the European Union (EU).
This order follows an initial contract awarded
in June 2023 and is also for delivery in 2024. The vaccines will be
stockpiled in another EU country thus expanding the EU’s capability
to respond to biological threats and emergencies in the future by
enabling rapid deployment of medical countermeasures to its member
states and other countries participating in the EU Civil Protection
Mechanism.
Paul Chaplin, President & CEO of Bavarian
Nordic, said: “We are pleased to continue supporting the initiative
from EU to build a stockpile of smallpox vaccines across Europe.
While our partnership with the European Health Emergency
Preparedness and Response Authority (HERA) has focused on
mitigating the immediate risk arising from the mpox outbreak in
2022, our recent contracts with rescEU serve to provide a long-term
readiness to respond to future health crises. This obviously
secures another order for next year confirming an ongoing demand,
but also the transition to stockpiling for future outbreaks, which
we see as a growing trend with other countries and
organizations.”
About the smallpox vaccineMVA-BN or
Modified Vaccinia Ankara-Bavarian Nordic (marketed as IMVANEX® in
Europe, JYNNEOS® in the U.S. and IMVAMUNE® in Canada) is a
non-replicating smallpox vaccine developed in collaboration with
the U.S. government to ensure supply of a smallpox vaccine for the
entire population, including immunocompromised individuals who are
not recommended vaccination with traditional replicating smallpox
vaccines. In addition to smallpox, the U.S. Food and Drug
Administration, Health Canada and the European Commission have also
approved the vaccine for use against mpox as the only vaccine
having obtained this to-date.
About rescEURescEU is part of the EU
Civil Protection Mechanism, established by the European Commission
as a safety net to protect citizens from disasters and manage
emerging risks. It includes, among others, reserves of medical
countermeasures which can be deployed in chemical, biological,
radiological, and nuclear (CBRN) emergencies. Read more:
https://civil-protection-humanitarian-aid.ec.europa.eu/what/civil-protection/resceu_en
About Bavarian NordicBavarian Nordic is a
fully integrated vaccines company focused on the research and
development, manufacturing and commercialization of life-saving
vaccines. We are a global leader in smallpox and mpox vaccines,
which have been developed through our long-standing partnership
with the U.S. Government to enhance the public health preparedness
and have a strong portfolio of vaccines for travelers and endemic
diseases. For more information visit www.bavarian-nordic.com.
Forward-looking statements This
announcement includes forward-looking statements that involve
risks, uncertainties and other factors, many of which are outside
of our control, that could cause actual results to differ
materially from the results discussed in the forward-looking
statements. Forward-looking statements include statements
concerning our plans, objectives, goals, future events, performance
and/or other information that is not historical information. All
such forward-looking statements are expressly qualified by these
cautionary statements and any other cautionary statements which may
accompany the forward-looking statements. We undertake no
obligation to publicly update or revise forward-looking statements
to reflect subsequent events or circumstances after the date made,
except as required by law.
ContactsEurope: Rolf Sass Sørensen, Vice
President Investor Relations, Tel: +45 61 77 47 43US: Graham
Morrell, Paddock Circle Advisors, graham@paddockcircle.com, Tel: +1
781 686 9600
Bavarian Nordic AS (TG:BV3)
過去 株価チャート
から 5 2024 まで 6 2024
Bavarian Nordic AS (TG:BV3)
過去 株価チャート
から 6 2023 まで 6 2024